期刊文献+

辛伐他汀联合非诺贝特治疗混合性高脂血症 被引量:5

下载PDF
导出
摘要 目的探讨联合应用小剂量辛伐他汀和非诺贝特治疗混合性高脂血症的疗效和安全性。方法共选择156例混合性高脂血症患者,随机分入辛伐他汀组(10mgqn,n=52)、非诺贝特组(100mgtid,n=50)和联合治疗组(辛伐他汀10mgqn+非诺贝特100mgtid,n=54),疗程6个月,观察治疗前后主要血脂参数的变化率、达标率及不良反应。结果(1)联合治疗组血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)和甘油三酯(TG)分别下降32%、35%、58%,血清高密度脂蛋白胆固醇(HDL-C)上升22%,其变化率明显优于单药治疗组(P﹤0.01)。(2)联合治疗组TC、LDL-C、TG三项均达标者占52%,明显高于单药治疗组(P﹤0.01)。(3)联合治疗组不良反应的发生率和单药治疗组相比差异无统计学意义(P﹥0.05)。结论小剂量辛伐他汀和非诺贝特联合治疗较单药治疗能更有效地改善混合性高脂血症患者的血脂异常,且具有良好的安全性。
出处 《中国现代医生》 2009年第2期89-90,共2页 China Modern Doctor
  • 相关文献

参考文献4

二级参考文献30

  • 1[5]Fichtlscherer S,Rosenberger G,Walter DH,et al.Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease[J].Circulation,2000.102(9):1000-1006.
  • 2Farnier M. Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative. Am J Cardiovasc Drugs,2003,3:169-178.
  • 3Snow V, Aronson MD, Hornbake ER, et al. Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med,2004,140: 644-649.
  • 4American diabetes association. Dyslipidemia management in adults with diabetes. Diabetes Care,2004,27(Suppl): S68-S71.
  • 5Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation,2002,106: 1024-1028.
  • 6Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol,1997,80: 106- 107.
  • 7Pauciullo P, Borgnino C, Paoletti R, et al. Effcacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study). Atherosclerosis,2000,150: 429-436.
  • 8Vega GL, Ma PT, Cater NB, et al. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J cardiol,2003,91: 956-960.
  • 9Martin G, Duez H, Blanquart C, et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARa and induces HDL apoA-I. J Cin Invest,2001,107:1423-1432.
  • 10Hodel C. Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett,2002,128:159-168.

共引文献228

同被引文献32

引证文献5

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部